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Background: Methylglyoxal is a typical 
2-oxoaldehyde derived from glycolysis. 
Results: Methylglyoxal inhibited the activity 
of yeast hexose transporters as well as 
mammalian glucose transporters (GLUT1 
and GLUT4), and enhanced the endocytosis 
of hexose transporters in yeast. 
Conclusion: Methylglyoxal inhibited 
glucose uptake in yeast cells. 
Significance: Phospholipase C and protein 
kinase C were involved in endocytosis of 
hexose transporters. 
 
Diabetes mellitus is characterized by an 
impairment of glucose uptake even though 
blood glucose levels are increased. 
Methylglyoxal is derived from glycolysis, 
and has been implicated in the 
development of diabetes mellitus, because 
methylglyoxal levels in blood and tissues 
are higher in diabetic patients than in 
healthy individuals. However, it remains 
to be elucidated whether such factors are a 
cause, or consequence, of diabetes. Here 
we show that methylglyoxal inhibits the 
activity of mammalian glucose 
transporters using recombinant 
Saccharomyces cerevisiae cells genetically 
lacking all hexosoe transporters but 
carrying cDNA for human GLUT1 or rat 
GLUT4. We found that methylglyoxal 
inhibits yeast hexose transporters also. 
Glucose uptake was reduced in a stepwise 
manner following treatment with 
methylglyoxal, i. e. a rapid reduction 
within 5 min, followed by a slow and 
gradual reduction. The rapid reduction 
was due to the inhibitory effect of 
methylglyoxal on hexose transporters, 
while the slow and gradual reduction 
seemed due to endocytosis, which leads to 
a decrease in the amount of hexose 
transporters on the plasma membrane. We 
found that Rsp5, a HECT-type ubiquitin 
ligase, is responsible for the ubiquitination 
of hexose transporters. Intriguingly, Plc1 
(phospholipase C) negatively regulated the 
endocytosis of hexose transporters in an 
Rsp5-dependent manner, although the 
methylglyoxal-induced endocytosis of 
hexose transpoters occurred irrespective 
of Plc1. Meanwhile, the internalization of 
hexose transporters following treatment 
with methylglyoxal was delayed in a 
mutant defective in protein kinase C. 
 
 
Glucose is an easy-to-use energy source 
for all kinds of cells. However, since cellular 
membranes is are not very permeable to 
glucose, cells are equipped with glucose 
transporters on the plasma membrane to take 
 2 
up glucose from outside of the cell. Many 
glucose transporters from prokaryotes to 
higher eukaryotes belong to the major 
facilitator superfamily (MFS), which is 
characterized by a single-polypeptide carrier 
with twelve transmembrane domains capable 
of transporting substrates across the 
membrane in response to a chemiosmotic 
gradient (1-3). For example, if the glucose 
concentration outside of cells is higher, 
glucose transporters take up glucose from 
outside, but when the intracellular glucose 
concentration is higher than outside, they 
pump out glucose. 
Although glucose is necessary as an 
energy source, glucose homeostasis in blood 
is crucial for mammals. Diabetes mellitus is 
characterized by a disruption of glucose 
homeostasis. When blood glucose levels 
increase upon food-intake, insulin is secreted 
from pancreatic β cells. The insulin signaling 
pathway in cells possessing insulin receptors 
is activated upon receipt of insulin, which 
leads to the translocation of a glucose 
transporter, GLUT4, to the plasma membrane 
thereby facilitating the influx of glucose (4). 
In type 1 diabetes, insulin secretion is 
defective; whereas in type 2 diabetes, cells 
are insensitive to insulin (insulin resistance), 
which seems to be caused by lifestyle. In 
both cases, cells are impaired in taking up 
glucose from blood, and consequently, 
hyperglycemic situations develop, which 
leads to the induction of several diabetic 
complications. One of the causes of diabetic 
complications is the accumulation of 
advanced glycation end products (AGEs), the 
synthesis of which is initiated by a 
non-enzymatic reaction between the aldehyde 
groups of glucose and amino groups of 
proteins, sometimes referred to as the 
Maillard reaction (5). Methylglyoxal (MG, 
CH3COCHO) is a ubiquitous 2-oxoaldehyde 
derived from glycolysis (6-8). Because MG 
contains two carbonyl groups, it has a 
20000-fold higher potential than glucose to 
produce AGEs (9). Therefore, MG levels and 
diabetic complications are closely related 
(10). The levels of MG in blood and tissues 
are higher in diabetic patients than healthy 
individuals (11-13). However, it remains to 
be solved whether high MG levels are a 
cause, or a consequence, of diabetes. 
Furthermore, the correlation between the 
onset of hyperglycemic conditions and an 
increase in MG levels has not been well 
investigated. 
One feature of diabetes mellitus is that the 
hyperglycemia is sustained even in a fasted 
state. The control of blood glucose levels 
mainly depends upon whether glucose 
transporters can transport glucose adequately 
(14, 15). To date, thirteen glucose 
transporters, GLUT1-GLUT12 and Hmit1, 
have been identified in mammals (2, 3). 
These transporters are responsible for the 
supply of glucose to various tissues, storage 
of glucose (glycogen) in liver, uptake of 
glucose in response to insulin, and sensing of 
blood glucose levels in pancreatic β cells 
(16-18). Mammalian glucose transporters are 
classified into three groups on the basis of 
primary structure (19). GLUT1-GLUT4 
belong to MFS (3). GLUT1, the first glucose 
transporter to be identified (20), is distributed 
in almost all tissues, and therefore, is thought 
to play a crucial role in glucose homeostasis 
under normal conditions (19). Since only 
GLUT4 is sensitive to insulin, it is involved 
in controlling blood glucose levels upon 
food-intake (15).  
Since yeast has served as a model of 
higher eukaryotes to reveal the mechanisms 
of many pivotal biological events, it is 
feasible that we will gain a clue as to the 
effect of MG on the function of mammalian 
GLUTs by analyzing the effect of MG on 
yeast glucose transporters. In the budding 
yeast Saccharomyces cerevisdiae, glucose 
transporters are referred to as hexose 
transporters (Hxts). S. cerevisiae has 
seventeen hexose transporters (Hxt1-Hxt17), 
and Gal2 as a galactose permease, all of 
which belong to MFS (21). We found that 
MG inhibits the activities of not only yeast 
Hxts but also mammalian GLUTs. 
Furthermore, MG induced endocytosis of 
yeast Hxts in an Rsp5 (HECT-type ubiquitin 
ligase)-dependent manner, thereby lowering 
glucose uptake. We found that protein kinase 
C (Pkc1) is involved in the MG-induced 
endocytosis of Hxts. Intriguingly, a 
deficiency in phospholipase C (Plc1) 
accelerated the internalization of Hxts under 
normal conditions in an Rsp5-dependent 
manner. However, the MG-induced 




MATERIALS AND METHODS 
 
Media 
The media used were YPD (2% glucose, 1% 
yeast extract, 2% peptone), YPMal (2% maltose, 
1% yeast extract, 2% peptone), SD (2% glucose, 
0.67% yeast nitrogen base w/o amino acids), SGal 
(2% galactose, 0.67% yeast nitrogen base w/o 
amino acids), and SMal (2% maltose, 0.67% yeast 
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nitrogen base w/o amino acids). Appropriate 
amino acids and bases were added to the SD, 
SGal, and SMal media as necessary. To select the 
HXT null mutant carrying a plasmid (URA3 
marker) harboring human GLUT1 cDNA or rat 
GLUT4 cDNA, cells were first spread on to 
YPMal agar (2%) plates after transformation, and 
cells grown on YPMal agar plates were replica 
plated on SMal agar plates without uracil. After 
verification of growth in SMal agar plates without 
uracil, cells were streaked on SD agar plates 
without uracil to verify the functional expression 
of GLUT1 and GLUT4. 
 
Strains 
Yeast strains used are summarized in Table 1. 
To construct an rsp5wimp (RSP5 
low-level-expression) mutant with the YPH250 
background, the natMX-inserted RSP5 promoter 
region of EN44 (22) was amplified by PCR with 
primers RSP5-F and RSP5-R-2. The PCR 
fragment was introduced into the RSP5 locus of 
YPH250. To construct a plc1∆ mutant, a 
plc1∆::HIS3 allele of YJF32 (23) was amplified 
by PCR with PLC1-F  and PLC1-R-2, and the 
product was introduced into the wild-type strain 
or rsp5wimp mutant of YPH250. To disrupt the 
SCH9 gene in YPH250, a sch9∆::TRP1 allele of 
TVH301 (24) was amplified with primers 
SCH9-F  and SCH9-R, and the amplicon was 
introduced into YPH250. Primers used in this 
study are summarized in Supplemental Table S1. 
 
Plasmids 
To construct the integration plasmids for 
Hxt1-GFP, Hxt2-GFP, and Hxt3-GFP, each HXT 
gene (HXT1, +401~ +1720; HXT2, +304~
+1640; and HXT3, +687~+1724) was amplified 
with the following primer sets: HXT1, 
HXT1-F-XbaI plus HXT1-R-XhoI; HXT2, 
HXT2-F-XbaI plus HXT2-R-XhoI; and HXT3, 
HXT3-F-XbaI plus HXT3-R-XhoI. Each PCR 
product was digested with XbaI and XhoI, and the 
resultant fragment was introduced into the XhoI 
and XbaI sites of YIp-NUP116-GFP (25), a 
pRS306 backbone plasmid, to replace NUP116 
with each HXT gene. The plasmids constructed 
(pHXT1-GFP, pHXT2-GFP, and pHXT3-GFP) 
were digested with HpaI, and the linearized DNA 
was introduced at the loci of HXT1, HXT2, and 
HXT3, respectively, to replace each gene 
containing a GFP tag.  
We verified that each Hxt-GFP protein is 
functional as glucose transporter by evaluating the 
recovery of growth of K73 cells in glucose 
medium. Because K73 lacks HXT1-7, it is not 
able to grow in glucose medium (26). However, 
since HXT1, HXT2, and HXT3 are deleted in K73, 
we cannot integrate GFP into each HXT locus to 
construct HXT-GFPs. So, we constructed 
plasmid-borne Hxt-GFPs. YIp-NUP116-GFP (25) 
was digested with XhoI and KpnI, and the 
XhoI-KpnI fragment containing GFP and NUF2 
3’ UTR was cloned into the XhoI-KpnI sites of 
pRS316. The resultant plasmid was named 
pRS316-GFP. Each HXT gene with its own 
promoter was amplified by PCR with the 
following primer sets: HXT1, HXT1-F-SacI plus 
HXT1-R-XhoI; HXT2, HXT2-F-SacI plus 
HXT2-R-XhoI; and HXT3, HXT3-F-SacI plus 
HXT3-R-XhoI. Each PCR product was digested 
with SacI and XhoI, and the resultant fragment 
was cloned into the SacI and XhoI sites of 
pRS316-GFP. The plasmids constructed 
(pRS316+HXT1-GFP, pRS316+HXT2-GFP, 
pRS316+HXT3-GFP) contain the same 
HXT-GFP allele with that of the 
genome-integrated HXT-GFP gene. K73 cells 
carrying each plasmid were able to grow in 
glucose medium, indicating that Hxt1-GFP, 
Hxt2-GFP, and Hxt3-GFP proteins are functional 
as glucose transporters.  
To construct the integration plasmids for 
HXT1-lacZ, HXT2-lacZ, and HXT3-lacZ, the 
promoter region of each HXT gene was amplified 
with the following primer sets: HXT1, 
HXT1-lacZ-F plus HXT1-lacZ-R; HXT2, 
HXT2-lacZ-F plus HXT2-lacZ-R; and HXT3, 
HXT3-lacZ-F plus HXT3-lacZ-R. Each PCR 
product was digested with SalI and EcoRI, and 
the resultant fragment was introduced into the 
SalI and EcoRI sites of YIp358R. The plasmids 
constructed (YIp358R+HXT1-lacZ, 
YIp358R+HXT2-lacZ, and 
YIp358R+HXT3-lacZ) were digested with NcoI, 
and integrated into the ura3-52 locus of the 
wild-type and plc1∆ mutant of YPH250.  
Plasmids used in this study are summarized in 
Table 2. 
 
Glucose uptake experiment 
Cells were cultured in SD medium until a log 
phase of growth, and 10 mM MG was added. 
Next, 5 ml of culture was taken at the prescribed 
time and transferred to a 15-ml falcon tube, and 
10 µl of [14C]-glucose (10.6 GBq/mmol, GE 
Healthcare Bio-Science) was added. Cells were 
then collected, washed with a chilled 0.85% NaCl 
solution, and suspended in 200 µl of distilled 
water. The cell suspension (150 µl) was mixed 
with 2 ml of a liquid scintillation cocktail 
(Ulutima-Flo AP, Perkin Elmer), and the amount 
of [14C]-glucose taken up by cells was measured 
using a scintillation counter (LS6500, 
BECKMAN COULTER). When cells were 
treated with latrunculin B (Lat-B, BIOMOL 
International), cells were pretreated with 100 µM 
Lat-B for 20 min prior to the addition of MG.  
 
Western blotting of GFP-tagged Hxts 
Cells carrying Hxt1-GFP, Hxt2-GFP, or 
Hxt3-GFP were cultured in 200-ml flasks 
containing 50 ml of SD medium until a log phase 
of growth (A610=~0.5), 10 mM MG was added, 
and the cells were incubated for the prescribed 
time. After being collected by centrifugation, cells 
were disrupted with glass beads in 100 µl of 
buffer A [50 mM Tris-HCl (pH 8.0), 10 mM 
EDTA, 5% glycerol, and protease inhibitor 
cocktail (Nacalai tesque)] using BeadSmash 12 
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(Waken). Cell homogenates were kept on ice for 2 
min, and transferred to another tube. The resulting 
glass beads were mixed with 100 µl of buffer A, 
and kept on ice for 2 min. The supernatant was 
mixed with the first cell homogenate, which was 
then centrifuged at low speed (3000 rpm for 2 min 
at 4ºC) to remove unbroken cells and cell debris, 
and the resultant supernatant, referred to as whole 
cell extract (WCE), was transferred to another 
tube. WCE was centrifuged at 14000 rpm for 15 
min at 4ºC, and the supernatant (soluble fraction) 
and pellet (insoluble fraction) were separated. The 
pellet was suspended in 75 µl of IPP150 buffer 
[10 mM Tris-HCl (pH 8.0), 150 mM NaCl, and 
0.1% NP40] containing 1% n-octyl-β-D-glucoside 
(Dojin) and protease inhibitor cocktail, and the 
suspension was kept on ice for 1 h, then 
centrifuged at 14000 rpm for 10 min at 4ºC. The 
supernatant was used as a membrane fraction. The 
soluble fraction (4 µg of protein) and membrane 
fraction (40 µg of protein) were subjected to SDS- 
PAGE. Separated proteins were transferred onto a 
PVDF membrane (Millipore) then detected using 
anti-GFP monoclonal antibody (Santa Cruz). 
Immunoreacted bands were visualized with a kit 
(Immobilon Western chemiluminescent HRP 
Substrate, Millipore) using a LAS-4000mini 
imaging system (FUJIFILM).  
 
Detection of ubiquitination 
To prepare the membrane fraction containing 
protein A-tagged Hxt2 (Hxt2-PA), MBY242 cells 
carrying the HXT2-PA gene (27) were cultured in 
SD medium until a log phase of growth, then 
transferred to fresh medium containing 0.1% 
glucose and 0.67% yeast nitrogen base (w/o 
amino acids) supplemented with appropriate 
amino acids and bases. After 1 h, cells were 
collected and disrupted as described above. WCE 
was ultracentrifuged at 50000 rpm for 1 h at 4ºC 
(himac CS120, Hitachi). The pellet was 
suspended in buffer A, and ultracentrifuged again. 
The resultant pellet was suspended in IPP150 
buffer containing 1% n-octyl-β-D-glucoside. After 
a 1-h incubation on ice, the cell suspension was 
centrifuged at 14000 rpm for 10 min at 4ºC, and 
the supernatant was transferred to a tube 
containing 50 µl of IgG beads (IgG SepharoseTM 
6 Fast Flow, Amersham Biosciences) equilibrated 
with IPP150 buffer. To adsorb the protein 
A-tagged Hxt2 to IgG beads, the mixture was 
gently rotated at 4ºC for 2 h. Subsequently, IgG 
beads were washed with 1 ml of IPP150 buffer 
three times, and then 0.9 ml of 100 mM 
glycine-HCl buffer (pH 3.5) was added to elute 
Hxt2-PA. After centrifugation, the supernatant 
was mixed with 100% trichloroacetic acid (final 
concentration, 10%), and the mixture was kept on 
ice for 10 min to precipitate proteins. After 
removal of the supernatant by centrifugation 
(14000 rpm, 10 min, 4ºC), the pellet was washed 
with acetone, and dried materials were dissolved 
in 25 µl of 1 M Tris-HCl (pH 7.5). After which, 
25 µl of 2x SDS-PAGE sample buffer was added, 
and the mixture was boiled for 3 min. Protein 
concentrations were determined using a RC DC 
Protein Assay kit (Bio-Rad). After SDS-PAGE 
followed by the transfer of separated proteins onto 
a PVDF membrane, Hxt2-PA and its 
ubiquitinated form were detected using 
anti-protein A (LOCKLAND) and anti-ubiquitin 
(BIOMOL International LP) antibodies, 
repectively. 
 
Western blotting of Hxts1/2 and GLUTs1/4 
KY73 (hxt1-7∆) (26) carrying a plasmid 
harboring HXT1 or HXT2, EBY.S7 (hxt∆ fgy1-1) 
(28) carrying GLUT1 cDNA, or EBY.F4-1 (hxt∆ 
fgy1-1 fgy4-1) (28) carrying GLUT4 cDNA was 
cultured in SD medium until a log phase of 
growth, and the membrane fraction was prepared 
by ultracentrifugation as described above. 
Anti-Hxt1, anti-Hxt2, anti-GLUT1, and 
anti-GLUT4 antibodies, which were donated by 
Dr. T. Kasahara, were used to detect proteins. To 
detect Pma1, an anti-Pma1 antibody (Encor 
Biotechnology) was used. 
 
Microscopy 
Cells carrying GFP-tagged proteins were 
cultured in SD medium until a log phase of 
growth, and 10 mM MG was added. The 
localization of each protein of interest was 
determined periodically using a fluorescence 
microscope. To stain vacuoles, 10 ml of culture 
was centrifuged to collect cells, which were then 
suspended in 196 µl of YPD medium. Four 
microliters of 2 mM FM4-64 (Biotium) was 
added to the cell suspension, and incubated at 
28ºC in the dark. After 20 min of incubation, 1 ml 
of a 0.85% NaCl solution was added to the cell 
suspension, and centrifuged to collect the cell. 
Cells were then suspended in fresh SD medium, 
and incubated for the prescribed time in the 





MG inhibits glucose uptake in yeast 
To explore the effect of MG on the 
function of hexose transporter (Hxt), we 
determined the rate of glucose uptake by 
yeast cells in the presence of MG. 
[14C]-Glucose was added to the culture in 
which yeast cells were growing 
logarithmically, and the amount of 
[14C]-glucose taken up by cells was 
determined. Figure 1A shows the levels of 
[14C]-glucose uptake after 15 min of addition 
of various concentrations of MG. Glucose 
uptake was inhibited in the presence of MG 
in a dose-dependent manner, and 
approximately 50% inhibition was attained 
by 10 mM MG. Next, we determined the 
time course of the effect of MG on inhibition 
of glucose uptake. The rate of uptake 
dropped by 35% within the first 5 min after 
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the addition of 10 mM MG, after which it 
declined gradually. It had decreased by 
approximately 60% after 60 min compared 
with that in the absence of MG. Several 
explanations are feasible regarding the 
reduction of glucose uptake following 
treatment with MG. For example, MG 
inhibited the activity of Hxts, or the number 
of Hxt molecules on the plasma membrane 
was decreased by endocytosis followed by 
degradation in vacuoles. To study these 
possibilities, we first determined whether 
endocytosis of Hxts occurred upon MG 
stress. 
 
MG induces the degradation of Hxts 
S. cerevisiae has seventeen HXT genes 
encoding glucose transporters. Since a 
mutant lacking one of these HXT genes is 
able to grow in a medium containing glucose 
as a source of carbon, these Hxts share 
redundant functions in terms of glucose 
uptake (21). However, since a mutant lacking 
HXT1 to HXT7 simultaneously looses the 
ability to grow in glucose medium (26), the 
rest of Hxts does not seem to play crucial 
roles in glucose uptake. The mRNAs of 
HXT1, HXT2, and HXT3 were abundant 
compared with those of other HXTs in cells 
cultured under ordinary laboratory conditions 
(i. e. containing 2% glucose) (29), so we 
determined the localization of GFP-tagged 
Hxt1, Hxt2, and Hxt3 as representatives of 
Hxts using a fluorescence microscope.  
As shown in Fig. 2A, Hxt1-GFP, 
Hxt2-GFP, and Hxt3-GFP were located on 
the plasma membrane at a log phase of 
growth, however, small punctate vesicles 
appeared after 15 min of MG treatment, 
which grew in size (30~60 min), and 
fluorescence derived from GFP-tagged 
proteins was observed in vacuoles (60~120 
min). We investigated whether membrane 
proteins in general are also internalized 
following treatment with MG; however, other 
proteins such as Pma1 (plasma membrane 
H+-ATPase) and Rvs161 (Amphiphysin-like 
lipid raft protein) were not internalized upon 
MG treatment (Fig. 2B). 
To verify whether the amount of Hxt1~3 
on the plasma membrane is decreased 
following treatment with MG, Western 
blotting was conducted. As shown in Fig. 2C, 
the levels of Hxt1-GFP, Hxt2-GFP, and 
Hxt3-GFP in membrane fractions decreased 
with time. By contrast, the levels of GFP 
protein in soluble fractions, which are 
derived from GFP-tagged Hxt1~3 by 
degradation in vacuoles, were increased. 
These results indicate that Hxt1~3 are 
internalized and degraded in the vacuole 
following treatment with MG. 
 
MG induces endocytosis of Hxts 
The endocytotic membrane vesicles fuse 
with endosomes, on which membrane the 
ubiquitin-modified cargo proteins are located, 
and subsequently, the components 
constituting the ESCRT (endosomal sorting 
complex required for transport) assemble on 
the endosomal membrane to internalize the 
cargo proteins into the lumen of endosomes, 
which are referred to as multivesiclar bodies 
(MVBs) (30). The deubiquitination is 
preceded by the internalization of cargo 
proteins into the luminal side of endosomes. 
In yeast cells, Doa4 is responsible for the 
deubiquitination of ubiquitin-modified cargo 
proteins in this process (31). The MVBs 
containing the internalized vesicles with 
deubiquitinated cargo proteins fuse with 
vacuoles, and consequently, degradation of 
MVBs occurs in the lumen of vacuoles. If 
deubiquitination of ubiquitin-modified cargo 
proteins does not occur, such endosomes are 
not able to develop to MVBs, and therefore, 
unable to fuse with vacuoles (31). Such 
endosomes form the so-called “ring-like 
structure” in the immediate vicinity of the 
vacuole, which can be visualized by staining 
endosomal membranes with a fluorescent dye, 
FM4-64 (32). To verify whether internalized 
Hxts are transported into the vacuole, we 
stained cells for vacuoles with FM4-64, and 
localization of Hxt1/2/3-GFPs was 
determined following treatment with MG. As 
shown in Fig. 3, GFP signals of each 
Hxt-GFP were observed in the vacuole, 
which was visualized with FM4-64. Next, to 
investigate whether transportation of Hxt1~3 
into the vacuole in the presence of MG is 
performed via the MVB pathway, we 
monitored the localization of Hxt1/2/3-GFPs 
in doa4∆ cells. As shown in Fig. 3, 
GFP-tagged Hxt1~3 accumulated in close 
proximity to the vacuolar membrane to form 
the ring-like structure, and no fluorescence 
signal was detected from the vacuolar lumen 
in doa4∆ cells. These results indicate that 
endocytosis of Hxts occurs upon MG 
treatment, and subsequently, internalized 
Hxts are transported into vacuoles via the 
MVB pathway for degradation. 
 
MG inhibits the activity of Hxt 
We have demonstrated that MG induces 
the internalization of Hxt1, Hxt2, and Hxt3, 
thereby seemingly reducing the ability of 
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yeast cell to take up glucose. The reduction 
of glucose uptake following treatment with 
MG occurred in a stepwise manner, i. e. a 
rapid response within 5 min, and a slow and 
gradual response thereafter (Fig. 1B). Since 
the internalization of Hxts occurred relatively 
slowly, the reduction in glucose uptake that 
occurred within 5 min is not likely dependent 
upon a decrease in the number of Hxts on the 
plasma membrane. To determine whether a 
rapid reduction of glucose uptake upon MG 
stress occurs irrespective of the endocytosis 
of Hxts, we measured glucose uptake under 
conditions where endocytosis is blocked. The 
actin cytoskeleton plays a crucial role in 
endocytosis, therefore, the depolymerization 
of F actin blocks endocytosis. Latrunculin B 
(Lat-B) as well as Lat-A depolymerizes F 
actin (33), thereby blocking endocytosis (34). 
We verified that endocytosis of 
Hxt1/2/3-GFPs following treatment with MG 
was blocked when Lat-B was present (Fig. 
4A). Then, we determined glucose uptake 
within the first 5 min of treatment with MG 
in the presence of Lat-B. As shown in Fig. 
4B, the reduction in glucose uptake was 
substantially the same as that without Lat-B, 
suggesting that MG inhibits the activity of 
Hxt per se, and a rapid reduction in glucose 
uptake occurs irrespective of the endocytosis 
of Hxts. 
  
MG inhibits Hxt1 and Hxt2 
Next, to explore whether the inhibitory 
effect of MG on glucose uptake differs 
depending upon the Hxt’s affinity for glucose, 
we used a mutant (K73) lacking HXT1-HXT7 
(hxt1-7∆) but carrying a plasmid harboring 
either HXT1 or HXT2. K73 cells are not able 
to grow in glucose medium but in maltose 
medium, because the maltose permeases in 
K73 remain intact (26). HXT1 codes for a 
low-affinity glucose transporter, and HXT2, a 
high-affinity transporter (21). We verified 
that the growth of K73 cells in glucose 
medium was restored by the introduction of a 
plasmid harboring either HXT1 or HXT2, 
which indicates that the introduced HXT1 and 
HXT2 are functionally active in K73 cells. 
We verified by Western blotting that the 
Hxt1 and Hxt2 proteins were adequately 
located on the plasma membrane (Fig. 5A). 
We determined the glucose uptake using the 
resultant transformants. As shown in Fig. 5B, 
the glucose uptake was inhibited in K73 cells 
expressing HXT1 or HXT2 following 
treatment with MG, suggesting that the 
inhibitory effect of MG on the activity of Hxt 
is exerted irrespective of its affinity for 
glucose.  
 
MG inhibits mammalian GLUTs 
Since we revealed that MG inhibits the 
activity of a yeast glucose transporter or Hxt, 
next we determined whether MG inhibits the 
activity of a mammalian glucose transporter 
(GLUT) also. To explore the effect of MG on 
the activity of GLUT using a yeast system, 
we used EBY.S7 carrying a human GLUT1 
cDNA, and EBY.F4-1 carrying a rat GLUT4 
cDNA. Both EBY.S7 and EBY.F4-1 lack all 
HXT genes (28). We verified the expression 
of human GLUT1 and rat GLUT4 by 
Western blotting using anti-GLUT1 and 
anti-GLUT4 antibodies, respectively (Fig. 
6A). In addition, the validity of the function 
of GLUT1 and GLUT4 expressed in yeast 
cells was verified by the ability of each 
transformant to grow in glucose medium, 
because these hxt null mutants (EBY.S7 and 
EBY.F4-1) are not able to grow in medium 
containing glucose as a sole source of carbon 
(28). As shown in Fig. 6B, glucose uptake in 
cells carrying human GLUT1 or rat GLUT4 
was lowered following treatment with MG in 
the presence of Lat-B. These results indicate 
that MG inhibits mammalian glucose 
transporters. 
 
MG-induced endocytosis of Hxts is dependent 
upon Rsp5 
The results obtained led us to conclude 
that the rapid reduction in glucose uptake 
following treatment with MG is due to its 
inhibitory effect on Hxts. So, next, we 
explored the mechanism behind the 
MG-induced endocytosis of Hxts.  
Generally, ubiquitination, in many cases 
mono-ubiquitination, is a trigger for the 
endocytosis of membrane-integral proteins 
on the plasma membrane (35). So, we 
determined whether ubiquitination of Hxt 
occurs following treatment with MG. In the 
ubiquitination of many transporters and 
permeases on the plasma membrane in S. 
cerevisiae, Rsp5, a HECT-type ubiquitin 
ligase, plays an important role (36). To 
explore whether MG-induced endocytosis of 
Hxt1~3 is dependent upon Rsp5, we 
constructed an rsp5wimp mutant. Because the 
RSP5 gene is essential, an rsp5 null mutant is 
unavailable. So, we inserted the natMX gene 
into the promoter of RSP5 to decrease its 
expression level (22). As shown in Fig. 7A, 
the MG-induced endocytosis of Hxts was 
inhibited in rsp5wimp cells. We verified that 
the amounts of Hxt1, Hxt2, and Hxt3 in 
membrane fractions did not decrease 
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following treatment with MG (Fig. 7B). To 
verify more directly whether the 
ubiquitination of Hxt occurs following 
treatment with MG, we conducted a 
pull-down experiment with protein A-tagged 
Hxt2 and IgG beads followed by Western 
blotting using anti-ubiquitin antibodies. As 
shown in Fig. 7C, the proportion of Hxt2 
having been ubiquitinated was increased 
following treatment with MG. Taken together, 
MG induces ubiquitination of Hxts in an 
Rsp5-dependent manner, and subsequently, 
endocytosis is induced to degrade them in the 
vacuole, which leads to a slow and gradual 
reduction of glucose uptake in the presence 
of MG. 
 
Phospholipase C negatively regulates 
endocytosis of Hxts 
Rsp5 contains the C2 domain which binds 
to phospholipids, such as 
phosphatidylinositols. The C2 domain of 
Rsp5 was verified to bind some species of 
phosphatidylinositols in vitro (37). Rsp5 has 
strong affinity for phosphatidylinositol 
4,5-bisphosphate (PtdIns(4,5)P2), which is 
distributed in the plasma membrane in yeast 
cells. Since Hxts are located on the plasma 
membrane, Rsp5 needs to approach the 
plasma membrane to interact with its 
substrates, or Hxts. It may be conceivable 
that Rsp5 associates with the plasma 
membrane through PtdIns(4,5)P2. PLC1 
codes for the sole phospholipase C in S. 
cerevisiae. Since Plc1 hydrolyzes 
PtdIns(4,5)P2 (23), it has an ability to bind 
PtdIns(4,5)P2. To explore the correlation 
between Rsp5 and Plc1, we investigated the 
effect of a Plc1-deficiency on the 
MG-induced endocytosis of Hxts. 
Intriguingly, strong fluorescence derived 
from Hxt1/2/3-GFPs was observed in 
vacuoles in plc1∆ cells despite an absence of 
MG (Fig. 8A). We investigated whether the 
fluorescence in the vacuoles is due to an 
increase in the expression of HXTs, thereby 
inducing the mislocalization of Hxts in 
vacuoles in plc1∆ cells. We monitored the 
expression of HXT1~3 using lacZ fusion 
genes, but found no distinct differences (data 
not shown). Next, we constructed a 
plc1∆rsp5wimp mutant to monitor the 
localization of Hxt1/2/3-GFPs. As shown in 
Fig. 8B, GFP-tagged Hxt1~3 are essentially 
located on the plasma membrane in such a 
mutant. Therefore, it seems that the deletion 
of PLC1 causes endocytosis of Hxt1~3 
constitutively in an Rsp5-dependent manner. 
However, Hxt1/2/3-GFPs on the plasma 
membrane disappeared following treatment 
with MG (Fig. 8A). These results indicate 
that the MG-induced endocytosis occurs 
independently of phospholipase C, although 
Plc1 can be defined as a negative regulator 
for endocytosis of Hxts under normal 
conditions. 
 
Involvement of TORC2 and Pkc1 in the 
MG-induced endocytosis of Hxt 
TORC2 (target of rapamycin complex 2) 
is a TOR kinase complex, consisting of Avo1, 
Avo2, Avo3, Bit61, and Lst8 (for review, see 
38). It has been reported that TORC2 is 
involved in the endocytosis of Ste2, a G 
protein-coupled α-factor receptor (39). To 
explore the involvement of TORC2 in the 
MG-induced endocytosis of Hxt, we used an 
RL25-1C strain whose AVO1 expression is 
regulated by GAL1 promoter (40). Avo1 is an 
essential component of TORC2 (40). The 
integrity of TORC2 was maintained when 
RL25-1C cells were grown in galactose 
medium, but the unimpaired state was lost 
after the shift to glucose medium due to the 
reduced expression of AVO1. As shown in 
Fig. 9A, endocytosis of Hxt1-GFP did not 
occur when RL25-1C cells were treated with 
MG in glucose medium. These results 
suggest that TORC2 is involved in the 
MG-induced endocytosis of Hxt. 
In this study, we have demonstrated that 
MG-induced endocytosis was repressed in 
the presence of Lat-B, a drug depolymerizing 
F actin. TORC2 plays crucial roles in the 
organization of the actin cytoskeleton (40). 
Besides TORC2, protein kinase C (Pkc1) is 
also involved in the organization of the actin 
cytoskeleton (41). We determined whether 
Pkc1 is also involved in the MG-induced 
endocytosis. Though PKC1 is an essential 
gene, a pkc1∆ mutant is able to grow when 
sorbitol at high concentrations is 
supplemented in the medium (41). As shown 
in Fig. 9B, the MG-induced endocytosis 
occurred in the presence of sorbitol in 
wild-type cells. Intriguingly, the timing of the 
internalization of Hxt1/2/3-GFPs was 
delayed in pkc1∆ cells following treatment 
with MG. Pkc1 activates the downstream 
mitogen-activated protein (MAP) kinase 
cascade consisting of Bck1, Mkk1/Mkk2, and 
Mpk1, which is also thought to be involved 
in actin organization (41). However, the 
MG-induced endocytosis of Hxt1 occurred in 
mpk1∆ cells with essentially the same timing 
as that in wild-type cells (Fig. 9C). These 
results suggest that Pkc1, but not Mpk1 MAP 
kinase, is involved in the endocytosis of Hxts 
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Inhibition of Hxts by MG 
To gain a clue as to the correlation 
between MG and glucose homeostasis, we 
determined the effect of MG on glucose 
uptake using a yeast system. We found that 
MG inhibits the glucose-uptake activity of a 
yeast hexose transporter (Hxt) and a 
mammalian glucose transporter (GLUT). It is 
believed that glucose transporters have two 
glucose-binding sites, one facing the outside 
of the cell (import site) and the other the 
inside (export site), and conformational 
change occurs when glucose binds to either 
the import site or export site to pass through 
the transporter (19). Several drugs that inhibit 
mammalian glucose transporters have been 
found, many of which are thought to compete 
with glucose for the glucose-binding sites. 
For example, cytochalasin B binds to Trp388 
and Trp412, both of which are located within 
the estimated export site of human GLUT1, 
which leads to the inhibition of glucose 
uptake (19). By contrast, phloretin, phlorizin, 
and 4,6-O-ethylidene-D-glucose bind to the 
estimated import site of GLUT1 (42, 43). 
Cytochalasin B, phloretin, and phlorizin 
inhibit the activity of GLUT4 also (44). 
However, these drugs do not inhibit yeast 
Hxts (T. Kasahara and M. Kasahara, personal 
communications). Furthermore, as far as we 
know, no drugs capable of inhibiting yeast 
Hxts have been found. In that sense, our 
finding is the first to show a chemical that 
inhibits yeast Hxts.  
It is known that MG reacts with Lys and 
Arg residues of proteins to form irreversible 
adducts, and with Cys residues reversibly 
(45). To gain a clue as to the mechanism how 
MG inhibits Hxt activity, we examined 
whether inhibition is reversible or not. Cells 
were treated with MG for 30 min, the timing 
at which Hxt activity was inhibited by 
approximately 60%, but a large proportion of 
Hxts has not yet been endocytosed, and 
subsequently cells were washed to remove 
MG and transferred to the fresh medium 
without MG. As shown in Fig. 1C, the levels 
of glucose uptake were reverted. These 
results suggest that the inhibitory effect of 
MG on Hxt activity is reversible. In contrast 
to mammalian GLUTs, no glucose-binding 
site has yet been identified in yeast Hxts, so 
we cannot assign which amino acid residues 
are the target of MG for inhibition; however, 
Cys might be one of the candidate amino acid 
residues to be involved in the MG-dependent 
inhibition of Hxt. MG may be a useful tool 
for analyzing the function of Hxts.  
We have demonstrated that MG inhibits 
the activity of not only yeast Hxts but also 
mammalian GLUT1 and GLUT4. Since MG 
is an endogenous metabolite, it exists in cells 
and plasma in mammals, i. e. it can be 
present both inside and outside of cells. 
Therefore, MG is accessible to the import site 
and export site of GLUT. Although the 
mechanism by which MG inhibits the activity 
of GLUTs has not yet been identified, our 
finding that exogenously added MG rapidly 
inhibits GLUT activity may provide new 
insights into the glucose homeostasis, which 
may be linked to diabetes mellitus. One of 
the pathologies of this disease is sustained 
hyperglycemia. As MG concentrations in 
plasma of diabetic patients are higher than 
those in healthy individuals (11-13), MG may 
inhibit GLUT1 constitutively expressed on 
the plasma membrane of many tissues, 
thereby lowering the efficacy of glucose 
uptake, which exacerbates the hyperglycemia. 
In addition, we have shown that MG inhibits 
GLUT4 also. Mammalian GLUT4 is usually 
contained in vesicles in cells carrying the 
insulin receptor. Upon the receipt of insulin, 
these GLUT4-containing vesicles are 
translocated to the plasma membrane, and 
subsequently, GLUT4 is exposed to the cell 
surface to take up glucose from blood (4). 
The fact that MG inhibits the activity of 
GLUT4 implies that MG interferes with 
insulin-responsive glucose uptake. Hence, the 
findings of this study using a yeast system 
lead us to propose that MG is involved in the 
onset and/or exacerbation of diabetes mellitus 
through impairment of glucose uptake. 
 
Endocytosis of Hxts by MG 
We have demonstrated that Hxt1~3 are 
ubiquitinated and internalized following 
treatment with MG, then transported into 
vacuoles via the MVB pathway for 
degradation. It has been reported that 
phosphorylation is preceded by 
ubiquitination in the endocytosis of many 
plasma membrane-integral proteins. For 
example, Ste2 is phosphorylated by casein 
kinase homologues (Yck1 and Yck2) upon 
the receipt of α-factor (46). Meanwhile, 
Hog1 phosphorylates Fps1, an 
aquaglyceroporin involved in the efflux of 
glycerol and uptake of acetic acid, thereby 
facilitating its degradation (47). We have 
previously reported that MG activates Hog1 
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MAP kinase (48), so we investigated whether 
the MG-induced endocytosis of 
Hxt1/2/3-GFPs is influenced in hog1∆ cells, 
but found no distinct differences in 
endocytosis between wild-type and hog1∆ 
cells (data not shown).  
We revealed that Rsp5 plays a crucial role 
in the MG-induced endocytosis of Hxts. 
Rsp5 contains a WW domain, through which 
it is able to interact with the target protein to 
be ubiquitinated containing the PY motif 
(Leu/Pro-Pro-Xaa-Tyr) (35). Rsp5 functions 
as the E3 enzyme (ubiquitin ligase) for many 
transporters and permeases on the plasma 
membrane, however, it is rare for such cargo 
proteins to contain a canonical PY motif (35). 
So, Rsp5 needs to interact with an adaptor 
protein containing the PY motif that is able to 
physically interact with cargo proteins. Since 
Hxts do not contain a PY motif, an adaptor 
protein or arrestin-related trafficking adaptor 
(Art) is necessary for Rsp5 to physically 
interact with Hxts for ubiquitination. Indeed, 
Art4/Rod1 is involved in the endocytosis of 
Hxt6 (22). Generally, arrestins are able to 
bind to the phosphorylated cargo proteins on 
the plasma membrane (49, 50). Therefore, it 
is feasible that Hxts are phosphorylated 
following treatment with MG prior to 
endocytosis. Hxt7 lacking the cytoplasmic 
domain at the N terminus was hardly 
internalized and degraded under conditions 
where the endocytosis of Hxt7 was induced 
(high-glucose conditions) (51). It has been 
reported that the PEST (Pro-Glu-Ser-Thr) 
sequence found at the N terminus of Hxt7 is 
involved in the degradation (52, 53). On the 
other hand, the PES (Pro-Glu-Ser) sequence 
found in Hxts and maltose permeases has 
been also implicated in the degradation 
process (54). Both PEST and PES motives 
contain serine and/or threonine that have the 
potential to be phosphorylated. So, we tried 
to detect the phosphorylation of Hxt upon 
MG stress using protein A-tagged Hxt2 
(Hxt2-PA) by pull-down experiments with 
IgG beads followed by Western blotting 
using anti-phospho-Ser and anti-phospho-Thr 
antibodies. However, as far as we could 
determine, phosphorylation of Hxt2 was not 
detected (data not shown). Nonetheless, we 
found that the timing of the MG-induced 
endocytosis of Hxt1/2/3-GFPs was delayed 
in pkc1∆ cells (Fig. 9B), so Pkc1 might be a 
candidate for the protein kinase responsible 
for the phosphorylation of Hxts for triggering 
endocytosis.  
The endocytosis of Hxts was virtually 
dependent upon Rsp5. Strikingly, we found 
that deficiency in Plc1 or Pkc1 affected the 
endocytosis of Hxts, therefore, both Plc1 and 
Pkc1 may influence the activity of Rsp5. The 
constitutive internalization of Hxt1~3 from 
the plasma membrane in plc1∆ cells was 
suppressed when the expression of Rsp5 was 
reduced (Fig. 8B), therefore, Plc1 might 
repress the function of Rsp5. One possible 
speculation is that Rsp5 and Plc1 might 
compete with each other for the binding to 
PtdIns(4,5)P2 on the plasma membrane. Rsp5 
contains C2 domain, which has the affinity to 
PtdIns(4,5)P2, enriched in the plasma 
membrane. Recently, Kaminska et al. (55) 
reported that GFP-tagged Rsp5 was located 
on the plasma membrane. Meanwhile, Plc1 
has the PH (pleckstrin homology) domain 
(56), through which it binds to PtdIns(4,5)P2. 
Therefore, if Plc1 is deleted, Rsp5 may be 
able to access PtdIns(4,5)P2 more easily, 
which allows Rsp5 to interact with cargo 
proteins thereby inducing the constitutive 
endocytosis of Hxts. 
By contrast, since MG-induced 
endocytosis was delayed in pkc1∆ cells, Pkc1 
may be involved in the activation of Rsp5 
following treatment with MG. Recently, a 
cationic amino acids transporter (CTA-1) in 
HEK293 cells was ubiquitinated by 
activation of protein kinase C (PKC), which 
is carried out by Nedd4-1 and Nedd4-2, 
mammalian orthologues of Rsp5 (57). 
Therefore, it is conceivable that Pkc1 may 
activate Rsp5 in yeast cells.  
In contrast to Pkc1, Mpk1 MAP kinase, 
which lies downstream of Pkc1, was not 
likely to be involved in the MG-induced 
endocytosis of Hxts (Fig. 9C). Regarding a 
role of Mpk1 in the endocytosis of Hxts, 
Soulard et al. (58) have reported that Mpk1 is 
involved in the rapamycin-induced 
endocytosis of Hxt1. Rapamycin is a specific 
inhibitor of TORC1 (target of rapamycin 
complex 1) (40). We also verified that 
rapamycin induces endocytosis of Hxt1~3 in 
an Rsp5-dependent manner using 
Hxt1/2/3-GFPs (Supplemental Fig. S1). 
Soulard et al. (58) reported that inhibition of 
TORC1 with rapamycin induces the 
phosphorylation of Bcy1 at Thr129, by which 
Bcy1 is activated as a negative regulatory 
subunit of protein kinase A (PKA). 
Schmelzle et al. (59) have reported that the 
rapamycin-induced endocytosis of Hxt1 was 
suppressed under conditions where the 
Ras/cAMP pathway was activated, i. e. 
deletion of BCY1, or introduction of the 
constitutively activated allele of RAS2 
(Ras2Val19). These results imply that PKA 
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negatively regulates endocytosis of Hxt1. 
Meanwhile, Soulard et al. (58) reported that 
Sch9, a direct substrate of TORC1, 
inactivates Mpk1. In addition, they reported 
that Mpk1 phosphorylates Thr129 of Bcy1 
directly in the presence of rapamycin, which 
leads to deactivation of PKA (58). 
Collectively, rapamycin treatment deactivates 
Sch9, which inactivates PKA through the 
Mpk1-mediated phosphorylation of Bcy1 at 
Thr129, thereby inducing endocytosis. If MG 
provokes the same regulatory circuit as 
rapamycin does, the Mpk1-mediated 
phosphorylation of Bcy1 might occur, 
leading to the inhibition of PKA thereby 
inducing endocytosis of Hxts. However, we 
have demonstrated that the MG-induced 
endocytosis of Hxts occurred even in mpk1∆ 
cells (Fig. 9C). Furthermore, we found that 
the MG-induced endocytosis of Hxts 
occurred in sch9∆ cells (Fig. 9D). Taken 
together, MG and rapamycin seem to induce 
endocytosis of Hxts via different pathways. 
Although Pkc1 lies upstream of the Mkp1 
MAP kinase cascade, Pkc1 seems to provoke 
the endocytosis of Hxts in the presence of 
MG through a pathway in which Mpk1 is not 
involved. 
Yeast has been used to study many pivotal 
biological events, because basic mechanistic 
principals are similar between yeasts and 
higher eukaryotes. This would also be the 
case for glucose uptake. The analysis of the 
intracellular distribution of GLUT1 and 
GLUT4 in mammalian cells following 
treatment with MG on the basis of our 
findings regarding the distribution of yeast 
Hxts would provide further insight into the 
correlation between MG and glucose 




1. Lagunas, R. (1993) FEMS Microbiol. Rev. 10, 229–242 
2. Walmsley, A. R., Barrett, M. P., Bringaud, F., and Gould, G. W. (1988) Trends Biochem. 
Sci. 23, 476-481 
3. Pao, S. S., Paulsen, I. T., and Saier, M. H. Jr. (1998) Microbiol. Mol. Biol. Rev. 62, 1-34 
4. Huang, S., and Czech, M. P. (2007) Cell Metab. 5, 237-252 
5. Dyer, D. G., Blackledge, J. A., Katz, B. M., Hull, C. J., Adkisson, H. D., Thorpe, S. R., 
Lyons, T. J., and Baynes, J. W. (1991) Z. Ernahrungswiss 30, 29-45 
6. Inoue, Y., and Kimura, A. (1995) Adv. Microb. Physiol. 37, 177-227 
7. Inoue, Y., Maeta, K., and Nomura, W. (2011) Semin. Cell. Dev. Biol. 22, 278-284 
8. Kalapos, M .P. (1999) Toxicol. Lett. 110, 145-175 
9. Turk, Z. (2010) Physiol. Res. 59, 147-156 
10. McLellan, A. C., Thornalley, P. J., Benn, J., and Sonksen, P. H. (1994) Clin. Sci. (Lond.) 
87, 21-29 
11. Beisswenger, P. J., Howell, S. K., Touchette, A. D., Lal, S., and Szwergold, B. S. (1999) 
Diabetes 48, 198-202 
12. Beisswenger, P. J., Howell, S. K., O'Dell, R. M., Wood, M. E., Touchette, A. D., and 
Szwergold, B. S. (2001) Diabetes Care 24, 726-732 
13. Lapolla, A., Flamini, R., Dalla Vedova, A., Senesi, A., Reitano, R., Fedele, D., Basso, E., 
Seraglia, R., and Traldi, P. (2003) Clin. Chem. Lab. Med. 41, 1166-1173 
14. Yki-Järvinen, H., Helve, E., and Koivisto, V. A. (1987) Diabetes 36, 892-896 
15. Thurmond, D. C., and Pessin, J. E. (2001) Mol. Membr. Biol. 18, 237-245 
16. Mueckler, M. (1994) Eur. J. Biochem. 219, 713-725 
17. Thorens, B. (1996) Am. J. Physiol. 270, G541-553 
18. Rea, S., and James, D. E. (1997) Diabetes 46, 1667-1677 
19. Uldry, M., and Thorens, B. (2004) Pflugers. Arch. 447, 480-489 
20. Mueckler, M., Caruso, C., Baldwin, S. A., Panico, M., Blench, I., Morris, H. R., Allard, W. 
J., Lienhard, G. E., and Lodish, H. F. (1985) Science 229, 941-945 
21. Özcan, S., and Johnston, M. (1999) Microbiol. Mol. Biol. Rev. 63, 554-569 
22. Nikko, E., and Pelham, H. R. (2009) Traffic 10, 1856-1867 
23. Flick, J. S., and Thorner, J. (1993) Mol. Cell. Biol. 13, 5861-5876 
24. Izawa, S., Takemura, R., and Inoue, Y. (2004) J. Biol. Chem. 279, 35469-35478 
 11 
25. Roosen, J., Engelen, K., Marchal, K., Mathys, J., Griffioen, G., Cameroni, E., Thevelein, J. 
M., De Virgilio, C., De Moor, B., and Winderickx, J. (2005) Mol. Microbiol. 55, 862-880 
26. Kruckeberg, A. L., Ye, L., Berden, J. A., and van Dam, K. (1999) Biochem. J. 339, 
299-307 
27. Bagnat, M., and Simons, K. (2002) Proc. Natl. Acad. Sci. U.S.A. 99, 14183-14188 
28. Wieczorke, R., Dlugai, S., Krampe, S., and Boles, E. (2003) Cell Physiol. Biochem. 13, 
123-134 
29. Ghaemmaghami, S., Huh, W. K., Bower, K., Howson, R. W., Belle, A., Dephoure, N., 
O'Shea, E. K., and Weissman, J. S. (2003) Nature 425, 737-741 
30. Katzmann, D. J., Odorizzi, G., and Emr, S. D. (2002) Nat. Rev. Mol. Cell Biol. 3, 893-905 
31. Nikko, E., and André, B. (2007) Traffic 8, 566-581 
32. Kranz, A., Kinner, A., and Kölling, R. (2001) Mol. Biol. Cell 12, 711-723 
33. Harrison, J. C., Bardes, E. S., Ohya, Y., and Lew, D. J. (2001) Nat. Cell Biol. 3, 417-420 
34. Engqvist-Goldstein, A. E., and Drubin, D. G. (2003) Annu. Rev. Cell. Dev. Biol. 19, 
287-332 
35. Léon, S., and Haguenauer-Tsapis, R. (2009) Exp. Cell Res. 315, 1574-1583 
36. Rotin, D., Staub, O., and Haguenauer-Tsapis, R. (2000) J. Membr. Biol. 176, 1-17 
37. Dunn, R., Klos, D. A., Adler, A. S., and Hicke, L. (2004) J. Cell Biol. 165, 135-144 
38. Powers, T., Aronova, S., and Niles, B. (2010) The Enzymes 27, 177-197 
39. deHart, A. K., Schnell, J. D., Allen, D. A., Tsai, J. Y., and Hicke, L. (2003) Mol. Biol. Cell 
14, 4676-4684 
40. Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., 
Oppliger, W., Jenoe, P., and Hall, M. N. (2002) Mol. Cell 10, 457-468 
41. Levin, D. E. (2005) Microbiol. Mol. Biol. Rev. 69, 262-291 
42. Kasahara, T., and Kasahara, M. (1996) Biochem. J. 315, 177-182 
43. Mueckler, M., Weng, W., and Kruse, M. (1994) J. Biol. Chem. 269, 20533-20538 
44. Kasahara, T., and Kasahara, M. (1997) Biochim. Biophys. Acta 1324, 111-119 
45. Maeta, K., Izawa, S., Okazaki, S., Kuge, S., and Inoue, Y. (2004) Mol. Cell. Biol. 24, 
8753-8764 
46. Hicke, L., Zanolari, B., and Riezman, H. (1998) J. Cell Biol. 141, 349-358 
47. Mollapour, M., and Piper, P. W. (2007) Mol. Cell. Biol. 27, 6446-6456 
48. Maeta, K., Izawa, S., and Inoue, Y. (2005) J. Biol. Chem. 280, 253-260 
49. Ferguson, S. S., Downey, W. E. 3rd, Colapietro, A. M., Barak, L. S, Ménard, L., and 
Caron, M. G. (1996) Science 271, 363-366 
50. Lohse, M. J., Benovic, J. L., Codina, J., Caron, M. G., and Lefkowitz, R. J. (1990) Science 
248, 1547-1550 
51. Krampe, S., and Boles, E. (2002) FEBS Lett. 513, 193-196 
52. Hein, C., Springael, J. Y., Volland, C., Haguenauer-Tsapis, R., and André, B. (1995) Mol. 
Microbiol. 18, 77-87 
53. Marchal, C., Haguenauer-Tsapis, R., and Urban-Grimal, D. (1998) Mol. Cell. Biol. 18, 
314-321 
54. Brondijk, T. H., van der Rest, M. E., Pluim, D., de Vries, Y., Stingl, K., Poolman, B., and 
Konings, W. N. (1998) J. Biol. Chem. 273, 15352-15357 
55. Kaminska, J., Spiess, M., Stawiecka-Mirota, M., Monkaityte, R., Haguenauer-Tsapis, R., 
Urban-Grimal, D., Winsor, B., and Zoladek, T. (2011) Eur. J. Cell. Biol. 90, 1016-1028 
56. Rebecchi, M. J., and Pentyala, S. N. (2000) Physiol. Rev. 80, 1291-1335 
57. Vina-Vilaseca, A., Bender-Sigel, J., Sorkina, T., Closs, E. I., and Sorkin, A. (2011) J. Biol. 
Chem. 286, 8697-8706 
58. Soulard, A., Cremonesi, A., Moes, S., Schütz, F., Jenö, P., and Hall, M. N. (2010) Mol. 
Biol. Cell 21, 3475-3486 
59. Schmelzle, T., Beck, T., Martin, D. E., and Hall, M. N. (2004) Mol. Cell. Biol. 24, 
338–351 
60. Levin, D. E., and Bartlett-Heubusch, E. (1992) J. Cell Biol. 116, 1221-1229 
61. Balguerie, A., Bagnat, M., Bonneu, M., Aigle, M., and Breton, A. M. (2002) Eukaryot. 
 12 
Cell 1, 1021–1031 




We thank Dr. T. Kasahara (Teikyo University, Japan) for valuable discussions, and generous 
gift of plasmids (Hxt1mnx-pVT, Hxt2mnx-pVT, pVT102-U/His-Xa-human-GLUT1, and 
pVT102-U/rat-GLUT4) and antibodies (anti-Hxt1, anti-Hxt2, anti-GLUT1, and anti-GLUT4 
antibodies), Dr. E. Boles (Heinrich-Heine-Universität, Germany) for EBY.S7 and EBY.F4-1, Dr. 
K. van Dam (The University of Amsterdam, The Netherlands) for KY73, Dr. M. N. Hall 
(University of Basel, Switzerland) for TB50a and RL25-1C, Dr. A. Breton (CNRS, France) for 
the Pma1-GFP and Rvs161-GFP plasmids, Dr. D. E. Levin (Boston University, USA) for 




Abbreviations used are: MFS, major facilitator superfamily; AGE, advanced glycation end 
product, MG, methylglyoxal; Hxt, hexose transporter; Lat-B, latrunculin B; WCE, whole cell 
extract; MVB, multivesiclar body; PtdIns(4,5)P2, phosphatidylinositol 4,5-bisphosphate; 
TORC2, target of rapamycin complex 2; MAP, mitogen-activated protein; TORC1, target of 
rapamycin complex 1; PKA, protein kinase A. 
 
FOOTNOTE 
This study was partially supported by a Grant-in-Aid for Scientific Research from the Ministry 
of Education, Science, Sports and Culture of Japan, and Grants from Institution of Fermentation, 






Fig. 1. Effect of MG on glucose uptake. A, cells (YPH250) were cultured in SD medium until a 
log phase of growth, and MG at various concentrations was added. After 15 min, glucose uptake 
was determined as described in Materials and Methods. B, cells (YPH250) were treated with 10 
mM MG for the period indicated, and glucose uptake was determined. C, glucose uptake was 
measured after addition of 10 mM MG periodically. After 30 min, cells were collected by 
centrifugation, washed and suspended in fresh SD medium without MG, and glucose uptake 
was determined (0 min was relatively taken as 100%). Data are averages for three independent 
experiments ± standard deviations. 
 
Fig. 2. MG induces internalization and degradation of Hxts. A, cells (YPH250) carrying 
Hxt1-GFP, Hxt2-GFP, or Hxt3-GFP were cultured in SD medium until a log phase of growth, 
and treated with 10 mM MG for the period indicated. The distribution of each GFP-tagged Hxt 
was observed using a fluorescence microscope. DIC, differential interference contrast. B, cells 
carrying Pma1-GFP or Rvs161-GFP were treated with 10 mM MG for the period indicated, and 
the distribution of  each GFP-tagged protein was determined. C, cells carrying Hxt1-GFP, 
Hxt2-GFP, or Hxt3-GFP were treated with MG as described in A, membrane and soluble 
fractions were prepared, and the amount of each GFP protein was determined by Western 
blotting. 
 
Fig. 3. Doa4 is involved in the endocytosis of Hxts. Wild type and doa4∆ mutant (BY4741 
background) carrying Hxt1-GFP, Hxt2-GFP, or Hxt3-GFP were cultured in SD medium until a 
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log phase of growth, and treated with 10 mM MG for the period indicated. The distribution of 
each Hxt-GFP was observed using a fluorescence microscope. Vacuolar membrane was stained 
by FM4-64. 
 
Fig. 4. MG inhibits the activity of Hxts. A, cells (YPH250) carrying Hxt1-GFP, Hxt2-GFP, or 
Hxt3-GFP were cultured in SD medium until a log phase of growth, and treated with 100 µM 
latrunculin B (Lat-B) for 20 min prior to treatment with 10 mM MG. The distribution of each 
Hxt-GFP was observed using a fluorescence microscope. B, cells were cultured in SD medium 
until a log phase of growth, and 100 µM Lat-B was added. After 20 min, [14C]-glucose was 
added. Glucose uptake in the first 5 min and 60 min after addition of MG was determined as 
described in Materials and Methods. Data are averages for three independent experiments ± 
standard deviations. 
 
Fig. 5. MG inhibits Hxt activity. A, K73 (hxt1-7∆) cells carrying Hxt1mnx-pYT harboring 
HXT1 (encoding a low-affinity glucose transporter) or Hxt2mnx-pVT harboring HXT2 
(encoding a high-affinity glucose transporter) were cultured in SD medium. A membrane 
fraction was prepared from each transformant as described in Materials and Methods. 
Expression of HXT1 and HXT2 was verified by Western blotting using anti-Hxt1 and anti-Hxt2 
antibodies, respectively. α-Pma1 indicates the loading control for the membrane fraction. B, 
glucose uptake of each transformant was determined as described in Materials and Methods. 
Data are averages for three independent experiments ± standard deviations. 
 
Fig. 6. MG inhibits mammalian GLUTs. A, EBY.S7 (hxt∆) cells carrying human GLUT1 cDNA 
were cultured in SD medium until a log phase of growth, and a membrane fraction was prepared 
as described in Materials and Methods. Expression of GLUT1 cDNA was verified by Western 
blotting using anti-GLUT1 antibodies. Glucose uptake in the first 5 min in the presence of 
Lat-B was determined. B, EBY.F4-1 (hxt∆) cells carrying rat GLUT4 cDNA were cultured in 
SD medium until a log phase of growth, and the expression of GLUT4 and glucose uptake were 
determined as described in A. α-Pma1 indicates the loading control for the membrane fraction. 
 
Fig. 7. Hxt is ubiquitinated in an Rsp5-dependent manner. A, cells (YPH250 background) of the 
wild type (WT) and rsp5wimp carrying Hxt1-GFP, Hxt2-GFP, or Hxt3-GFP were cultured in SD 
medium until a log phase of growth, and treated with 10 mM MG for the period indicated. The 
distribution of each GFP-tagged Hxt was observed using a fluorescence microscope. B, rsp5wimp 
cells (YPH250 background) carrying Hxt1-GFP, Hxt2-GFP, or Hxt3-GFP were treated with 
MG as described in A, soluble and membrane fractions were prepared, and the amount of each 
GFP protein or Pma1 was determined by Western blotting. The intensity of each Hxt-GFP band 
in membrane fractions was quantified by densitometry, and normalized with Pma1 as a loading 
control of each lane. The level of each Hxt-GFP protein at 0 min was relatively taken as 1.0. 
Data are averages for three independent experiments ± standard deviations. C, MBY242 cells 
carrying protein A-tagged Hxt2 (HXT2-PA) were cultured in SD medium until a log phase of 
growth and treated with MG for the period indicated in the figure. A membrane fraction was 
prepared by ultracentrifugation. This was followed by a pull-down experiment using IgG beads. 
Ubiquitination (α-Ub) and the amount of Hxt2-PA (α-PA) were determined using anti-ubiquitin 
and anti-PA antibodies, respectively, as described in Materials and Methods. 
 
Fig. 8. Hxts are constitutively internalized in plc1∆ cells. A, plc1∆ cells (YPH250 background) 
carrying Hxt1-GFP, Hxt2-GFP, or Hxt3-GFP were cultured in SD medium until a log phase of 
growth, and treated with 10 mM MG for 120 min. The distribution of each GFP-tagged protein 
was observed using a fluorescence microscope. B, cells (YPH250 background) of the wild type 
(WT), plc1∆, rsp5wimp, and plc1∆rsp5wimp carrying Hxt1-GFP, Hxt2-GFP, or Hxt3-GFP were 




Fig. 9. Involvement of TORC2 and Pkc1 in the MG-induced endocytosis of Hxts. A, TB50a 
(wild type, WT) and RL25-1C (TB50a background with GAL1 promoter-driven AVO1, 
pGAL-AVO1) cells carrying Hxt1-GFP were cultured in SGal medium until a log phase of 
growth, and transferred to SD medium. After 10 h, 10 mM MG was added, and the distribution 
of Hxt1-GFP was determined using a fluorescence microscope. B, cells (DL100 background) of 
the wild type (WT) and pkc1∆ carrying Hxt1-GFP were cultured in SD medium containing 0.5 
M sorbitol, and 10 mM MG was added. The distribution of Hxt1/2/3-GFPs was determined 
using a fluorescence microscope. C, cells (DL100 background) of the wild type (WT) and 
mpk1∆ carrying Hxt1-GFP were cultured in SD medium containing 0.5 M sorbitol until a log 
phase of growth, and the distribution of Hxt1-GFP was determined after addition of 10 mM MG. 
D, cells (YPH250 background) of the wild type (WT) and sch9∆ carrying Hxt1-GFP, Hxt2-GFP 





Yeast strains used in this study 
 
Strain Relevant genotype/description Source/reference 
YPH250 MATa trp∆1-1 his3-∆200 leu2-∆1 lys2-801 ade2-101 
ura3-52 
Lab stock 
BY4741 MATa his3∆1 leu2∆0 met15∆0 ura3∆0 Invitrogen 
rsp5wimp YPH250, natMX was inserted into the promoter of RSP5 This study 
plc1∆ YPH250, plc1∆::HIS3 This study 
plc1∆rsp5wimp YPH250, plc1∆::HIS3 rsp5wimp  This study 
sch9∆ YPH250, sch9∆::TRP1 This study 
doa4∆ BY4741, doa4∆::KanMX4 This study 
mpk1∆ DL100, mpk1∆::KanMX4 This study 
EN44  BY4741, natMX was inserted into the promoter of RSP5 22 
MBY242  MATa his4 ura3 leu2 lys2 bar1 HXT2-PA::URA3 27 
YJF32   MATa ura3-52 lys2-801_amber ade2-101_ochre trp1-Δ63 
his3-Δ200 leu2-Δ1 plc1∆::HIS3 
23 
TVH301   MATa ade2-1 can1-100 his3-11,15 leu2-3,112 trp1-1 
ura3-1 sch9::TRP1 
25 
KY73 MATa hxt1∆::HIS3::∆hxt4 hxt5::LEU2 hxt2∆::HIS3 
hxt3∆::LEU2::hxt6 hxt7::HIS3 gal2∆::DR ura3-52 
his3-11,15 lue2-3,112 MAL2 SUC2 GAL MEL 
26 
EBY.S7 MATa hxt1-17∆ gal2∆ agt1∆ stl1∆ leu2-3,112 ura3-52 
trp1-289 his3-∆1 MAL2-8c SUC2 hxt∆ fgy1-1 
28 
EBY.F4-1 MATa hxt1-17∆ gal2∆ agt1∆ stl1∆ leu2-3,112 ura3-52 
trp1-289 his3-∆1 MAL2-8c SUC2 hxt∆ fgy1-1 fgy41 
28 
TB50a MATa his3 leu2-3, 112 ura3-52 rme1 trp1 40 
RL25-1C TB50a, [KanMX4]-GAL1p-3HA-AVO1 40 
DL100 MATa leu2-3,112 trp1-1 ura3-52 his4 can1 60 




Plasmids used in this study 
 
Plasmid Description Source/reference 
pHXT1-GFP 
 
pRS306 (integrate-type, URA3 marker) backbone, for 




pRS306 (integrate-type, URA3 marker) backbone, for 
replacement of endogenous HXT2 with HXT2-GFP 
This study 
pHXT3-GFP pRS306 (integrate-type, URA3 marker) backbone, for 
replacement of endogenous HXT3 with HXT3-GFP 
This study 
pRS316+PMA1-GFP pRS316 (CEN-type, URA3 marker) harboring Pma1-GFP 61 
pFL44+RVS161-GFP pFL44 (CEN-type, URA3 marker) harboring Rvs161-GFP 61 
YIp358R+HXT1-lacZ YIp358R (integrate-type, URA3 marker) backbone, for 
fusion with HXT1 and lacZ 
This study 
YIp358R+HXT2-lacZ YIp358R (integrate-type, URA3 marker) backbone, for 
fusion with HXT2 and  lacZ 
This study 
YIp358R+HXT3-lacZ YIp358R (integrate-type, URA3 marker) backbone, for 
fusion with HXT3 and lacZ 
This study 
Hxt1mnx-pVT pVT102-U (2µ-type, URA3 marker) backbone, for 
expression of HXT1 
62 
Hxt2mnx-pVT pVT102-U (2µ-type, URA3 marker) backbone, for 




pVT102-U (2µ-type, URA3 marker) backbone, for 
expression of human GLUT1 cDNA 
Kasahara, T. 
unpublished 
pVT102-U/rat-GLUT4 pVT102-U (2µ-type, URA3 marker) backbone, for 
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Figure 4 Yoshida et al. 
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Figure 8 Yoshida et al. 
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Figure 9 Yoshida et al. 
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Supplemental Table S1 
 


















HXT1-lacZ F 5'-TACCTCTAAAGAGTGTCGACCAACTGA-3' 
HXT1-lacZ R 5'-ATCGGGAGGAATTCTCATGATTTTACGTAT-3' 
HXT2-lacZ F 5'-TTCTAGTCGACAGGTCAGTTAAGGCACAGA-3' 
HXT2-lacZ R 5'-AGTAGGAATTCCAGACATTATGTTGCTTTA-3' 
HXT3-lacZ F 5'-TCTCTTCCGGCGTCGACTTTCAACCTAAGG-3' 
HXT3-lacZ R 5'-TGGAGGAATTCTCATGATTGTTTAACTCAG-3' 
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Supplemental Fig. S1. MG induces internalization and degradation of Hxts. 
A, cells (YPH250) carrying Hxt1-GFP, Hxt2-GFP, or Hxt3-GFP were cultured 
in SD medium until a log phase of growth, and treated with 200 ng/ml 
rapamycin (Rap) for the period indicated. The distribution of each GFP-tagged 
Hxt was observed using a fluorescence microscope. B, rsp5wimp cells (YPH250 
background) carrying Hxt1-GFP, Hxt2-GFP, or Hxt3-GFP were treated with 
200 ng/ml rapamycin (Rap) for 60 min. 
